Zoetis Stock News

Zoetis Inc (NYSE:ZTS, ETR:ZOE) shares took a hit Friday after a Wall Street Journal report that suggested the company's arthritis shots may have sickened dogs and cats. The arthritis shots, Librela an

An article in The Wall Street Journal highlights the scrutiny over the company's arthritis treatments for pets.

Zoetis Inc.'s stock ZTS, -7.77% tumbled 7% Friday to lead S&P 500 decliners, after a Wall Street Journal report that the company's arthritis shots Librela and Solensia may have sickened pet cats and d

The latest trading day saw Zoetis (ZTS) settling at $165.69, representing a -0.1% change from its previous close.

The SPDR S&P 500 ETF Trust had a 3.27% return in March, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares. The top 15 dividend growth stocks for April 2024 offer an average dividend

Lululemon offered weaker-than-expected guidance in its fourth-quarter earnings report. Southwest cut its guidance in response to the crisis at Boeing.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024. Chief Executive Officer Kristin Pec

It is possible for retail investors to consistently beat the market by owning above-average blue chip dividend growth stocks. Hard work, research, and staying rational are key factors in outperforming

Zoetis Inc. has shown unique compounding results since spinning off from Pfizer, with double-digit EPS and dividend growth CAGRs since inception. The loneliness epidemic is driving demand for companio

The SPDR S&P 500 ETF Trust had a 5.22% return in February, outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares.

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Zoetis is the world's largest producer of medicine and vaccinations for pets and livestock. It's also been incredibly profitable for its shareholders since its spinoff from Pfizer.

Beating the S&P 500 is difficult due to skewed market returns favoring a few high-performing stocks.

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck rig

Kristin Peck, Zoetis CEO, joins 'Money Movers' to discuss what Zoetis' guidance says about Peck's business expectations, factors that are contributing to their growth relative to fundamentals, and how